A Theoretical Approach to an HIV Vaccine Targeting CCR5

Arundhathi Jathin

doi:10.58445/rars.967

##article.authors##

Arundhathi Jathin Valencia High School

DOI:

https://doi.org/10.58445/rars.967

Keywords:

HIV, Vaccine, CCR5

Abstract

One of the world’s biggest issues is the spread of bloodborne pathogens. One of such pathogens is the Human Immunodeficiency Virus (HIV). HIV weakens the immune system, making it more difficult for patients to fight off infections. CCR5 is a co-receptor found on the surface of many immune cells in the body. While its function is not fully characterized, it is frequently implicated in HIV infection, and is required for HIV to infect CD4+ T-cells. In this paper, we investigated the potential for developing a vaccine against the CCR5 co-receptor so that our immune system can produce antibodies against the receptor and block it so that HIV would be unable to penetrate T-cells. Additionally, we discussed the potential side effects of blocking the CCR5 co-receptor, we described the type of vaccine required to generate such an antibody response, and we evaluated the potential efficacy of such a vaccine in both preventing HIV transmission and potentially curing individuals living with HIV. Finally, we compare this approach to some current medications for HIV and discuss multiple studies that have explored similar CCR5-blocking approaches.

References

Barmania, F., & Pepper, M. S. (2013). C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection. Applied & Translational Genomics, 2, 3–16. https://doi.org/10.1016/j.atg.2013.05.004

Barouch, D. H. (2008). Challenges in the development of an HIV-1 vaccine. Nature, 455(7213), 613–619. https://doi.org/10.1038/nature07352

Battistini Garcia, S. A., & Guzman, N. (2020). Acquired Immune Deficiency Syndrome CD4+ Count. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK513289/

Bogers, W. M., Bergmeier, L. A., Ma, J., Oostermeijer, H., Wang, Y., Kelly, C. G., ten Haaft, P., Singh, M., Heeney, J. L., & Lehner, T. (2004). A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. AIDS, 18(1), 25. https://journals.lww.com/aidsonline/fulltext/2004/01020/a_novel_hiv_ccr5_receptor_vaccine_strategy_in_the.3.aspx

CDC. (2020). HPV Vaccine. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/vpd/hpv/hcp/vaccines.html

Clinical trial of HIV vaccine begins in United States and South Africa. (2023, September 20). National Institutes of Health (NIH). https://www.nih.gov/news-events/news-releases/clinical-trial-hiv-vaccine-begins-united-states-south-africa

CNN, H. K. (2021, June 5). 40 years ago, the first cases of AIDS were reported in the US. CNN. https://www.cnn.com/2021/06/05/health/aids-40-anniversary-first-reported-cases-trnd/index.html

Dadonaite, B. (2019, December 1). Antiretroviral therapy has saved millions of lives from AIDS and could save more. Our World in Data. https://ourworldindata.org/art-lives-saved

Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022). mRNA vaccines in the prevention and treatment of diseases. MedComm, 3(3), e167. https://doi.org/10.1002/mco2.167

HIV.gov. (2023a, January 20). HIV Vaccines. HIV.gov. https://www.hiv.gov/hiv-basics/hiv-prevention/potential-future-options/hiv-vaccines/

HIV.gov. (2023b, April 12). Pre-Exposure Prophylaxis: PrEP Medication. HIV.gov. https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis/

Huang, Y., Paxton, W. A., Wolinsky, S. M., Neumann, A. U., Zhang, L., He, T., Kang, S., Ceradini, D., Jin, Z., Yazdanbakhsh, K., Kunstman, K., Erickson, D., Dragon, E., Landau, N. R., Phair, J., Ho, D. D., & Koup, R. A. (1996). The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Medicine, 2(11), 1240–1243. https://doi.org/10.1038/nm1196-1240

Hunter, Z., Smyth, H. D., Durfee, P., & Chackerian, B. (2009). Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine. Vaccine, 28(2), 403–414. https://doi.org/10.1016/j.vaccine.2009.10.035

Hussein, M., Molina, M. A., Berkhout, B., & Herrera-Carrillo, E. (2023). A CRISPR-Cas Cure for HIV/AIDS. International Journal of Molecular Sciences, 24(2), 1563. https://doi.org/10.3390/ijms24021563

Justiz, A. A., & Gulick, P. G. (2022, September 20). HIV and AIDS syndrome. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK534860/

KempnerMarch 14, M., & 2019. (2019, March 14). The Genetic Mutation Behind the Only Apparent Cure for HIV. Www.thebodypro.com. https://www.thebodypro.com/article/genetic-mutation-behind-hiv-cure

Lewis, T., & Gendelman, H. (2007, January 1). CCR5 Chemokine Receptor (S. J. Enna & D. B. Bylund, Eds.). ScienceDirect; Elsevier. https://www.sciencedirect.com/science/article/abs/pii/B9780080552323601904

Lopalco, L. (2011). Natural anti-CCR5 antibodies in HIV-infection and -exposure. Journal of Translational Medicine, 9(S1). https://doi.org/10.1186/1479-5876-9-s1-s4

Luckheeram, R. V., Zhou, R., Verma, A. D., & Xia, B. (2012). CD4+T Cells: Differentiation and Functions. Clinical and Developmental Immunology, 2012(925135), 1–12. https://doi.org/10.1155/2012/925135

Maraviroc (Celsentri). (2021, July 27). CATIE - Canada’s Source for HIV and Hepatitis c Information. https://www.catie.ca/maraviroc-celsentri

Maraviroc (UK-427857) | ≥99%(HPLC) | Selleck | CCR antagonist. (n.d.). Selleckchem.com. https://www.selleckchem.com/products/Maraviroc.html

Mayo Clinic. (2021, November 5). How do different types of COVID-19 vaccines work? Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/different-types-of-covid-19-vaccines/art-20506465

MedlinePlus. (2022, November 21). What are mRNA vaccines and how do they work? Medlineplus.gov. https://medlineplus.gov/genetics/understanding/therapy/mrnavaccines/

NIH. (2021). HIV and AIDS: The Basics | NIH. Hivinfo.nih.gov. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-aids-basics

NIH. (2021b, February 8). FDA-Approved HIV Medicines | HIVINFO. Hivinfo.nih.gov. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines

Office of Infectious Disease and HIV/AIDS Policy (OIDP). (2022, December 22). Vaccine Types. HHS.gov. https://www.hhs.gov/immunization/basics/types/index.html

Post-Exposure Prophylaxis (PEP). (n.d.). WebMD. https://www.webmd.com/hiv-aids/post-exposure-prophylaxis

Rao, P. K. S. (2009). CCR5 inhibitors: Emerging promising HIV therapeutic strategy. Indian Journal of Sexually Transmitted Diseases and AIDS, 30(1), 1–9. https://doi.org/10.4103/2589-0557.55471

World Health Organization (WHO). (2023). HIV and AIDS. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hiv-aids

A Theoretical Approach to an HIV Vaccine Targeting CCR5

##article.authors##

DOI:

Keywords:

Abstract

References

Downloads

Posted

Categories

License